false
0001974640
0001974640
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
November 13, 2023
Apogee Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
Delaware |
001-41740 |
88-0588063 |
(State of Incorporation or
Organization) |
(Commission File Number) |
(I.R.S. Employer Identification
No.) |
221 Crescent Street, Building 17, Suite 102b,
Waltham, MA, 02453
(Address of Principal Executive Offices, including Zip Code)
(650) 394-5230
(Registrant’s telephone
number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.00001 per share |
|
APGE |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Condition. |
On November 13, 2023, Apogee
Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended
September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
This Item 2.02 and the Press Release attached hereto as Exhibit 99.1,
insofar as they disclose information regarding the Company’s results of operations and financial condition for the quarter ended
September 30, 2023, are being furnished to the Securities and Exchange Commission.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits. The following exhibit is being furnished
herewith:
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Apogee Therapeutics, Inc. |
|
|
|
Date: November 13,
2023 |
By: |
/s/ Michael Henderson |
|
|
Michael Henderson |
|
|
Chief Executive Officer |
Exhibit 99.1
Apogee Highlights Corporate Progress and Reports
Third Quarter 2023 Financial Results
Phase 1 clinical trial of APG777, a fully optimized,
subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers
expected mid-2024; on track to begin Phase 2 in moderate-to-severe atopic dermatitis in 2024
Announcing our finalized nomination of development
candidate for APG808, a potentially best-in-class, femtomolar affinity, subcutaneous extended half-life
antibody targeting IL-4Rα, a target with clinical validation across eight Type 2 allergic diseases in 4Q 2023
Well-capitalized with $422.9 million in cash following
upsized IPO supporting operating runway into 4Q 2026
San Francisco, CA and Waltham, MA, November 13, 2023 - Apogee
Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of
atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications,
today provided business updates and reported third quarter 2023 financial results.
“I am proud of our team’s execution during the third quarter
and 2023 overall. We continue to deliver against our operating plan, advancing our lead program, APG777 for AD, into a first-in-human
healthy volunteer study ahead of schedule while progressing our portfolio of potentially best-in-class biologics designed to significantly
improve therapeutic options for patients across the largest markets in I&I”, said Michael Henderson, M.D., Chief Executive Officer
of Apogee. “We expect to report initial PK and safety data from the Phase 1 trial for APG777 in mid-2024, a potentially key de-risking
milestone, which we believe could demonstrate our potential benefit relative to the current standard of care, including optimized exposures,
low variability, and extended half-life. Alongside the advancements in APG777, we are excited to announce the selection of a development
candidate for our second program, APG808, and remain on track to enter the clinic in healthy volunteers in 2024 followed by a Phase 2
trial in COPD.
Pipeline Highlights and Upcoming Milestones
| · | Dosing
underway in Phase 1 trial of APG777: APG777 is a novel, subcutaneous (SQ) extended
half-life monoclonal antibody targeting IL-13 – a critical cytokine in inflammation
and a primary driver of AD. The Phase 1 trial is a randomized, double-blind, placebo-controlled
clinical trial designed to evaluate the safety, tolerability and pharmacokinetics (PK) of
single-ascending and multiple-ascending doses of APG777. Apogee initiated dosing of healthy
volunteers ahead of schedule in August 2023. The Phase 1 clinical trial objectives are to: |
| o | Establish safety and PK; |
| o | Set Phase 2 induction regimen to achieve at least equivalent exposures as lebrikizumab, a first-generation IL-13 antibody; and |
| o | Support testing of maintenance dosing regimens of every 2 or 3 months while maintaining the minimal concentration of APG777 at a similar
level to lebrikizumab |
Apogee expects initial safety and PK data from the Phase
1 trial in mid-2024, a potentially key de-risking milestone given APG777 is targeting a validated mechanism. The goal of the Phase 1 trial
is to support potential dosing every 2 to 3 months compared to the current standard of care of every 2 to 4 weeks. Apogee believes this
potential for significant differentiation compared to leading therapies may contribute to a best-in-class profile for APG777. Pending
positive PK and safety data, the company plans to advance into a randomized, double-blind, placebo-controlled, 16-week Phase 2 proof-of-concept
trial in moderate-to-severe patients with AD in 2024 with data expected in the second half of 2025.
| · | Finalized nomination of APG808 development candidate
in 4Q 2023: APG808
is an SQ extended half-life mAb targeting IL-4Rα, a target with clinical validation across eight Type 2 allergic diseases. APG808
has similar binding femtomolar affinity for IL-4Rα as a first generation mAb, DUPIXENT,
and has demonstrated similar inhibition to DUPIXENT across
three in vitro assays which measure downstream functional inhibition of the IL-13/IL-4 pathway (pSTAT6 induction, inhibition of
TF-1 proliferation, and inhibition of TARC secretion).
Additionally, in Apogee’s head-to-head studies of APG808 and DUPIXENT in non-human
primates, APG808 showed a significantly longer half-life than DUPIXENT. In these preclinical
studies, APG808’s half-life was up to 26 days, as compared to 12 days for DUPIXENT. Based
on these preclinical studies, we believe that the longer half-life could support dosing either every 6 weeks or every 2 months in the
clinic, which, if future clinical trials are successful, would represent a significant improvement
compared to DUPIXENT which is currently being investigated with every 2-week dosing in COPD.
APG808 remains on track to enter the clinic in healthy volunteers in 2024 followed by a Phase 2 trial in COPD (pending data from
the Phase 1 trial and following the submission of an IND to support the Phase 2 trial). |
Recent Corporate Highlights
| · | Completed
$345 million upsized Initial Public Offering (IPO): In July, the company completed
its upsized IPO and sold 20,297,500 shares of common stock, which included the full exercise
of the underwriters’ option to purchase additional shares at a price to the public
of $17.00 per share. The aggregate gross proceeds to Apogee from the offering before deducting
underwriting discounts and commissions and other offering expenses were approximately $345
million. |
| · | Presented
preclinical data for APG777: In October, at the 2023 European Academy of Dermatology
and Venereology (EADV) Congress held in Berlin, Germany, Apogee presented preclinical data
that highlighted the potential advantages of APG777 over current therapeutic agents targeting
IL-13, including half-life. |
| · | Expanded
board of directors and leadership team: In August, healthcare veteran and former Chairman,
President and CEO of Prometheus Biosciences, Mark C. McKenna, was appointed Chairman of
the Apogee board of directors. Matt Batters also joined Apogee in August as General Counsel,
a role he most recently served in at Arvinas, Inc. |
Upcoming Investor Events
Apogee plans to participate in the following upcoming events:
| · | Stifel 2023 Healthcare Conference, November 14, New York, NY |
| · | Jefferies London Healthcare Conference, November 15, London, UK |
| · | Evercore ISI 6th Annual HealthCONx Conference, November 28, Miami,
FL |
Third Quarter Financial Results
| · | Cash Position: As of September 30, 2023, Apogee had a total cash balance
of $422.9 million. Apogee expects that its existing cash will enable it to fund its current operating expenses and capital expenditure
requirements into the fourth quarter of 2026. |
| · | Research & Development (R&D) Expenses: R&D expenses for
the third quarter of 2023 were $17.1 million, compared to $9.9 million for the third quarter of 2022. R&D expenses increased primarily
due to further development of the company’s APG777 and APG808 programs and advancement of its pipeline, as well as increases in
personnel costs, including share-based compensation expense, associated with the growth of its R&D team. |
| · | General and Administrative (G&A) Expenses: G&A expenses for
the third quarter of 2023 were $7.2 million, compared to $0.6 million for the third quarter of 2022. G&A expenses increased primarily
due to increases in personnel costs, including share-based compensation, associated with the growth of the company’s G&A team,
as well as increased costs related to being a public company, including for legal, IT and professional services, and to support the growth
of the business. |
| · | Net Loss: Net loss for the third quarter of 2023 was $20.8 million,
compared to the net loss for the third quarter of 2022 which was $19.7 million. |
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company seeking
to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD)
and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations
of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life
and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the
treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and
meaningful benefit to patients underserved by today’s standard of care.
Forward Looking Statements
Certain statements in this press release may constitute “forward-looking
statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for
our current and future product candidates and programs, plans for our current and future clinical trials, plans for clinical trial design,
the anticipated timing of the initiation of and results from our clinical trials, potential clinical benefit and half-life of APG777,
APG808 and any other potential programs, and expectations regarding the time period over which our capital resources will be sufficient
to fund our anticipated operations. Words such as “may,” “might,” “will,” “objective,”
“intend,” “should,” “could,” “can,” “would,” “expect,” “believe,”
“design,” “estimate,” “predict,” “potential,” “develop,” “plan”
or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking
statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking
statements, which are based on information available to the company on the date of this release. These forward-looking statements are
based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those
set forth in Apogee’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company’s
control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions
and related volatility, expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials
and research and development programs; expectations regarding the timing, completion and outcome of our clinical trials; the unpredictable
relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals;
liquidity and capital resources; and other risks and uncertainties identified in our Quarterly Report of 10-Q for the quarterly period
ended June 30, 2023, filed with the SEC on August 28, 2023, and subsequent disclosure documents we may file with the SEC. Apogee claims
the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee
expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise,
except as required by law.
APOGEE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except unit/share data)
| |
SEPTEMBER 30, | | |
DECEMBER 31, | |
| |
2023 | | |
2022 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 188,269 | | |
$ | 151,890 | |
Marketable securities | |
| 234,585 | | |
| - | |
Prepaid expenses and other current assets | |
| 3,567 | | |
| 165 | |
Total current assets | |
| 426,421 | | |
| 152,055 | |
Total assets | |
$ | 426,421 | | |
$ | 152,055 | |
Liabilities, preferred units and stockholders’ equity/members’ deficit | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,208 | | |
$ | 418 | |
Accrued expenses | |
| 15,970 | | |
| 9,562 | |
Total current liabilities | |
| 17,178 | | |
| 9,980 | |
Total liabilities | |
| 17,178 | | |
| 9,980 | |
Commitments and contingencies | |
| | | |
| | |
Series A Preferred Units; no units authorized, issued and outstanding at September 30, 2023; 20,000,000 units authorized, issued and outstanding as of December 31, 2022 | |
| - | | |
| 28,971 | |
Series B Preferred Units; no units authorized, issued and outstanding at September 30, 2023; 45,089,212 units authorized, issued and outstanding as of December 31, 2022 | |
| - | | |
| 148,496 | |
Stockholders’ equity/members’ deficit: | |
| | | |
| | |
Common Units; no units authorized, issued and outstanding at September 30, 2023; 5,000,000 units authorized, issued and outstanding as of December 31, 2022 | |
| - | | |
| 2,251 | |
Incentive Units; no units authorized, issued and outstanding at September 30, 2023; 12,412,473 units authorized, 9,648,374 issued and 1,625,086 outstanding as of December 31, 2022 | |
| - | | |
| 2,142 | |
Preferred Stock; 10,000,000 authorized, $0.00001 par value, no shares issued and outstanding September 30, 2023; No shares authorized, issued and outstanding at December 31, 2022 | |
| - | | |
| - | |
Common Stock; 400,000,000 authorized, $0.00001 par value, 50,674,296 issued and 48,017,621 outstanding as of September 30, 2023; No shares authorized, issued and outstanding at December 31, 2022 | |
| - | | |
| - | |
Additional paid-in capital | |
| 501,143 | | |
| - | |
Accumulated other comprehensive income | |
| 135 | | |
| - | |
Accumulated deficit | |
| (92,035 | ) | |
| (39,785 | ) |
Total stockholders’ equity/members’ deficit | |
| 409,243 | | |
| (35,392 | ) |
Total liabilities, preferred units and stockholders’ equity/members’ deficit | |
$ | 426,421 | | |
$ | 152,055 | |
APOGEE THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)
(In thousands)
| |
| | |
| | |
| | |
PERIOD FROM | |
| |
| | |
| | |
NINE MONTHS | | |
FEBRUARY 4, 2022 | |
| |
THREE MONTHS ENDED SEPTEMBER 30, | | |
ENDED SEPTEMBER 30, | | |
(INCEPTION) TO | |
| |
2023 | | |
2022 | | |
2023 | | |
SEPTEMBER 30, 2022 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 17,069 | | |
$ | 9,885 | | |
$ | 39,470 | | |
$ | 15,578 | |
General and administrative | |
| 7,236 | | |
| 622 | | |
| 16,378 | | |
| 1,050 | |
Total operating expenses | |
| 24,305 | | |
| 10,507 | | |
| 55,848 | | |
| 16,628 | |
Loss from operations | |
| (24,305 | ) | |
| (10,507 | ) | |
| (55,848 | ) | |
| (16,628 | ) |
Other income (expense), net: | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 3,465 | | |
| — | | |
| 3,598 | | |
| — | |
Other financing expense | |
| — | | |
| (9,150 | ) | |
| — | | |
| (9,150 | ) |
Total other income (expense), net | |
| 3,465 | | |
| (9,150 | ) | |
| 3,598 | | |
| (9,150 | ) |
Net loss | |
$ | (20,840 | ) | |
$ | (19,657 | ) | |
$ | (52,250 | ) | |
$ | (25,778 | ) |
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics
Noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com
v3.23.3
Cover
|
Nov. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 13, 2023
|
Entity File Number |
001-41740
|
Entity Registrant Name |
Apogee Therapeutics, Inc.
|
Entity Central Index Key |
0001974640
|
Entity Tax Identification Number |
88-0588063
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
221 Crescent Street
|
Entity Address, Address Line Two |
Building 17
|
Entity Address, Address Line Three |
Suite 102b
|
Entity Address, City or Town |
Waltham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02453
|
City Area Code |
650
|
Local Phone Number |
394-5230
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.00001 per share
|
Trading Symbol |
APGE
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024